Six-month compliance with antidepressant medication in the treatment of major depressive disorder

被引:54
|
作者
Demyttenaere, Koen [1 ]
Adelin, Albert [2 ]
Patrick, Mesters [3 ]
Walthere, Dewe [3 ]
Katrien, De Bruyckere
Michele, Sangeleer
机构
[1] Univ Hosp Gasthuisberg, Dept Psychiat, B-3000 Louvain, Belgium
[2] Univ Hosp, Dept Biostat, Ghent, Belgium
[3] Eli Lilly Mt St Guibert, European Dev Ctr, Mont St Guibert, Belgium
关键词
antidepressants; compliance; major depressive disorder;
D O I
10.1097/YIC.0b013e3282f1c1d8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The investigation of compliance in patients with major depressive disorder (in drop-outs versus completers and in first episode versus recurrent episode patients). A total of 85 outpatients with major depressive disorder were followed for 6 months. Different dimensions of compliance were investigated: drop-outs versus completers and their medication adherence (with electronic monitoring). General linear mixed models were applied to examine the time courses of adherence. Drop-out rates were higher in younger patients and in patients with a lower initial depression severity. The adherence during 6 months of treatment with selective serotonin reuptake inhibitors was above 80 in 70% of the patients. The adherence decreased by 2.5% per month and decreased more than three times more rapidly in drop-outs (from baseline to time of drop-out). A medical visit resulted in a temporary increase in pill intake. General linear mixed model analysis showed that the predicted outcome was worse in drop-outs than in completers and worse in recurrent episode patients than in first episode patients (the former showing a higher adherence). Adherence decreases with time during 6 months of treatment with antidepressants and is influenced by demographic and clinical variables. Completers show a higher adherence than drop-outs. The outcome was worse in recurrent episode patients than first episode patients although they had a higher adherence.
引用
收藏
页码:36 / 42
页数:7
相关论文
共 50 条
  • [41] The effect of antidepressant treatment on quality of life in patients with major depressive disorder
    Aydemir, O.
    Ergun, H.
    Kesebir, S.
    Soygur, H.
    Tulunay, C. F.
    BIPOLAR DISORDERS, 2010, 12 : 5 - 5
  • [42] Impact of medical comorbid disease on antidepressant treatment of major depressive disorder
    Iosifescu D.V.
    Bankier B.
    Fava M.
    Current Psychiatry Reports, 2004, 6 (3) : 193 - 201
  • [44] Six-month paroxetine treatment of premenstrual dysphoric disorder: Continuous versus intermittent treatment protocols
    Wu, Kuan-Yi
    Liu, Chia-Yih
    Hsiao, Mei-Chun
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2008, 62 (01) : 109 - 114
  • [45] Compliance with antidepressant medication among prison inmates with depressive disorders
    Baillargeon, J
    Contreras, S
    Grady, JJ
    Black, SA
    Murray, O
    PSYCHIATRIC SERVICES, 2000, 51 (11) : 1444 - 1446
  • [46] Neuroanatomical dimensions in medication-free individuals with major depressive disorder and treatment response to SSRI antidepressant medications or placebo
    Cynthia H. Y. Fu
    Mathilde Antoniades
    Guray Erus
    Jose A. Garcia
    Yong Fan
    Danilo Arnone
    Stephen R. Arnott
    Taolin Chen
    Ki Sueng Choi
    Cherise Chin Fatt
    Benicio N. Frey
    Vibe G. Frokjaer
    Melanie Ganz
    Beata R. Godlewska
    Stefanie Hassel
    Keith Ho
    Andrew M. McIntosh
    Kun Qin
    Susan Rotzinger
    Matthew D. Sacchet
    Jonathan Savitz
    Haochang Shou
    Ashish Singh
    Aleks Stolicyn
    Irina Strigo
    Stephen C. Strother
    Duygu Tosun
    Teresa A. Victor
    Dongtao Wei
    Toby Wise
    Roland Zahn
    Ian M. Anderson
    W. Edward Craighead
    J. F. William Deakin
    Boadie W. Dunlop
    Rebecca Elliott
    Qiyong Gong
    Ian H. Gotlib
    Catherine J. Harmer
    Sidney H. Kennedy
    Gitte M. Knudsen
    Helen S. Mayberg
    Martin P. Paulus
    Jiang Qiu
    Madhukar H. Trivedi
    Heather C. Whalley
    Chao-Gan Yan
    Allan H. Young
    Christos Davatzikos
    Nature Mental Health, 2024, 2 (2): : 164 - 176
  • [47] Valproic acid as an antidepressant in major depressive disorder
    Davis, LL
    Petty, F
    PSYCHOPHARMACOLOGY BULLETIN, 1996, 32 (03) : 430 - 430
  • [48] An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: A pilot study
    Spronk, D.
    Arns, M.
    Barnett, K. J.
    Cooper, N. J.
    Gordon, E.
    JOURNAL OF AFFECTIVE DISORDERS, 2011, 128 (1-2) : 41 - 48
  • [49] Six-Month Longitudinal Patterns of Mental Health Treatment Utilization by Older Adults With Depressive Symptoms
    Gum, Amber M.
    Iser, Lindsay
    King-Kallimanis, Bellinda L.
    Petkus, Andrew
    DeMuth, Anne
    Schonfeld, Lawrence
    PSYCHIATRIC SERVICES, 2011, 62 (11) : 1353 - 1360
  • [50] Keywords: Major depressive disorder Antidepressant treatment Noradrenergic and specific serotonergic antidepressant Mirtazapine Mianserin
    Fugger, Gernot
    Bartova, Lucie
    Fabbri, Chiara
    Fanelli, Giuseppe
    Zanardi, Raffaella
    Dold, Markus
    Kautzky, Alexander
    Rujescu, Dan
    Souery, Daniel
    Mendlewicz, Julien
    Zohar, Joseph
    Montgomery, Stuart
    Serretti, Alessandro
    Kasper, Siegfried
    JOURNAL OF AFFECTIVE DISORDERS, 2022, 312 : 225 - 234